About Us.
Cognyxx Pharmaceuticals is pioneering a new class of innate immune-modulating treatments. With CGX304 at the forefront, we aim to actively clear pathogenic amyloid deposits and in parallel confer immediate protection for cardiomyocytes thereby promoting a rapid and robust effect on disease course.
What drives us
The realization that our lead candidate CGX304 possesses a unique three dimensional structure allowing it to target multiple pathogenic transthyretin species, lead us to strongly believe it will stand a ‘best in class’ disease modifying therapeutic to address all ATTR amyloidosis driven disorders
Our Scientific Approach
Targeting the Root Cause
We neutralize and clear misfolded transthyretin (TTR), the root cause of ATTR cardiomyopathy and polyneuropathy.
Dual Benefit
Our therapies combine immediate protection of neurons and cardiomyocytes with long-term reduction of amyloid burden.
Truly Disease-Modifying
By clearing toxic deposits and restoring organ function, we aim to deliver transformative therapies.
Our Pipeline
1
Indication 1: ATTR Cardiomyopathy (ATTR-CM)
A first-in-class therapeutic antibody engineered to combat transthyretin amyloidosis at the source. It binds selectively to misfolded and aggregated TTR while sparing the normal protein. In preclinical models, it cleared cardiac amyloid deposits and improved cardiac function.
​​
​​
​
Stage: Preclinical
3
A monoclonal antibody designed to recognize and bind misfolded transthyretin in ATTR polyneuropathy. It neutralizes toxic oligomers and amyloid fibrils while promoting clearance through innate immune cells. In preclinical models, it reduced amyloid in nerves, protected neurons, and improved neurological function.
​​​
Stage: Preclinical
Indication 2:
ATTR Plyneuropathy
(ATTR-PN)
